Gouty Arthritis (Gout) - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 118 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gouty Arthritis (Gout) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Gouty Arthritis (Gout) - Pipeline Review, H1 2015', provides an overview of the Gouty Arthritis (Gout)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gouty Arthritis (Gout), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Gouty Arthritis (Gout) Overview 10
Therapeutics Development 11
Pipeline Products for Gouty Arthritis (Gout) - Overview 11
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis 12
Gouty Arthritis (Gout) - Therapeutics under Development by Companies 13
Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes 15
Gouty Arthritis (Gout) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Gouty Arthritis (Gout) - Products under Development by Companies 20
Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes 23
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development 24
AstraZeneca PLC 24
Celtaxsys, Inc. 25
CymaBay Therapeutics, Inc. 26
Delenex Therapeutics AG 27
Immune Response BioPharma, Inc. 28
IOmet Pharma 29
JW Pharmaceutical Corporation 30
Kissei Pharmaceutical Co., Ltd. 31
LG Life Sciences, Ltd. 32
Nimbus Therapeutics, LLC 33
Nippon Chemiphar Co., Ltd. 34
Omni Bio Pharmaceutical Inc. 35
Opsona Therapeutics Ltd. 36
PLx Pharma Inc. 37
Polaris Pharmaceuticals, Inc. 38
Selecta Biosciences, Inc. 39
Takeda Pharmaceutical Company Limited 40
Teijin Pharma Limited 41
TWi Pharmaceuticals, Inc. 42
Wellstat Therapeutics Corporation 43
Gouty Arthritis (Gout) - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
arhalofenate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CTX-4430 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
diacerein - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DLX-2323 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
DLX-2681 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Fc-Alpha-1 Antitrypsin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
FcAAT-2 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
FcAAT-3 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
febuxostat - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
febuxostat XR - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
IR-888 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
KUX-1151 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
LC-350189 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
lesinurad sodium - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibody to Inhibit S100A9 Protein for Neurodegenerative Diseases, Chronic Inflammation and Autoimmune Disorders - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
NC-2500 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ND-2110 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ND-2158 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ND-346 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pegadricase - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
pegadricase - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PL-4100 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
PN-XXXX - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
RDEA-3170 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
REV-002 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
RLBN-1001 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
RLBN-2020 Series - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RLBN-3010 Series - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecule Inflammasome Modulator Programme - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
URC-102 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
uriSHELS - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
X-0002 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
XEN-102 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
XEN-104 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Gouty Arthritis (Gout) - Recent Pipeline Updates 99
Gouty Arthritis (Gout) - Dormant Projects 107
Gouty Arthritis (Gout) - Discontinued Products 109
Gouty Arthritis (Gout) - Product Development Milestones 110
Featured News & Press Releases 110
Mar 23, 2015: CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City 110
Mar 03, 2015: Vince & Associates Clinical Research Completes CymaBay Therapeutics Clinical Trial of Arhalofenate in Combination with Febuxostat 110
Feb 26, 2015: Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease 110
Feb 24, 2015: CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares 111
Jan 22, 2015: Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency 112
Jan 12, 2015: Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat 112
Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan 114
Nov 26, 2014: Revive Therapeutics Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout 114
Nov 18, 2014: Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic 114
Nov 16, 2014: AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting 115
Appendix 117
Methodology 117
Coverage 117
Secondary Research 117
Primary Research 117
Expert Panel Validation 117
Contact Us 117
Disclaimer 118

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), H1 2015 11
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 13
Number of Products under Development by Companies, H1 2015 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Comparative Analysis by Unknown Stage Development, H1 2015 19
Products under Development by Companies, H1 2015 20
Products under Development by Companies, H1 2015 (Contd..1) 21
Products under Development by Companies, H1 2015 (Contd..2) 22
Products under Investigation by Universities/Institutes, H1 2015 23
Gouty Arthritis (Gout) - Pipeline by AstraZeneca PLC, H1 2015 24
Gouty Arthritis (Gout) - Pipeline by Celtaxsys, Inc., H1 2015 25
Gouty Arthritis (Gout) - Pipeline by CymaBay Therapeutics, Inc., H1 2015 26
Gouty Arthritis (Gout) - Pipeline by Delenex Therapeutics AG, H1 2015 27
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H1 2015 28
Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H1 2015 29
Gouty Arthritis (Gout) - Pipeline by JW Pharmaceutical Corporation, H1 2015 30
Gouty Arthritis (Gout) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 31
Gouty Arthritis (Gout) - Pipeline by LG Life Sciences, Ltd., H1 2015 32
Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H1 2015 33
Gouty Arthritis (Gout) - Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 34
Gouty Arthritis (Gout) - Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 35
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd., H1 2015 36
Gouty Arthritis (Gout) - Pipeline by PLx Pharma Inc., H1 2015 37
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 38
Gouty Arthritis (Gout) - Pipeline by Selecta Biosciences, Inc., H1 2015 39
Gouty Arthritis (Gout) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 40
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H1 2015 41
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H1 2015 42
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H1 2015 43
Assessment by Monotherapy Products, H1 2015 44
Number of Products by Stage and Target, H1 2015 46
Number of Products by Stage and Mechanism of Action, H1 2015 48
Number of Products by Stage and Route of Administration, H1 2015 50
Number of Products by Stage and Molecule Type, H1 2015 52
Gouty Arthritis (Gout) Therapeutics - Recent Pipeline Updates, H1 2015 99
Gouty Arthritis (Gout) - Dormant Projects, H1 2015 107
Gouty Arthritis (Gout) - Dormant Projects (Contd..1), H1 2015 108
Gouty Arthritis (Gout) - Discontinued Products, H1 2015 109